Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities

Riociguat is licensed for the therapy of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to investigate whether age and comorbidities influence its tolerability and efficacy. Retrospectively, we analyzed data of tolerability, non-invasive, and invasive efficacy at baseline...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnikel, Michaela, Kneidinger, Nikolaus, Arnold, Paola, Waelde, Andrea, Behr, Jürgen, Milger, Katrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877433/
https://www.ncbi.nlm.nih.gov/pubmed/35207354
http://dx.doi.org/10.3390/jcm11041084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877433/
https://www.ncbi.nlm.nih.gov/pubmed/35207354
http://dx.doi.org/10.3390/jcm11041084

Ejemplares similares